|
|
Theophylline02-10-00189 Theophylpine 25 50 kg F.D or anhydrous USP23, BP98 P.D 02-10-00190 Thymol USP23 NF18 ; , BP98 02-10-00191 Titanium dioxide USP23, BP98 25 50 kg F.D or P.D 25-50 kg F.D or P.D or multilayer papere bag lined with nylon on pallte 5 kg alum. Can. 25 kg F.D or P.D 25-50 kg F.D or P.D or aor alum. Sachet in hard carton box 5 kg alum. Can. Or alum. Sachet in hard carton box. TOXICITY -dyspnea lasting a few seconds due to bronchoconstriction in 20% -transient facial flushing 30% -no hypotension -no negative inotropic effects DRUG INTERACTIONS: -methylxanthines i.e., theophylline ; are competitive antagonists of adenosine -dipyridamole prevents uptake into cells & requires reduced adenosine doses. Theophylline pregnancy160 ; Complete triploidy was found in lymphocyte cultures from a stillborn full-term female infant with a birth weight of 1, 000 g. The child had a ventricular septal defect of the heart but no other macroscopic internal or external malformations. The mother, who had a history of prolonged anti-asthmatic medication ephedrine, phenobarbitone, diphenylhydramine and theophylline ; , displayed a high incidence of satelite associations and chromatid breakages in her cultured lymphocytes. mutagenicity 161 ; A dietary case-control study based on 818 newly diagnosed breast cancer patients was conducted between 1975 and 1978. The role of coffee and total methylxanthine intake was evaluated in breast cancer patients was compared to two matched control populations surgical controls and neighborhood controls ; . A nonsignificant negative association was found between coffee and or methylxanthine consumption and breast cancer. carcinogenicity breast ; 162 ; carcinogenicity breast ; Relationship between methylaxanthine consumption and breast cancer using data from a case-control study which included 1, 510 cases and 1882 controls identified through a nation-wide breast cancer screening program. No evidence of a positive association between methylxanthine consumption and risk of breast cancer was observed. Particularly in women diagnosed after age of 50 some suggestion of a negative association was found. The results of caffeine alone were similar to those of total methylxanthines. 163 ; carcinogenicity breast ; In a population-based case control study including 451 cases and one control mateched to each case, methylxanthine intake was measured by means of self-administered, quantitative food frequency questionnaire. Intake of caffeine was calculated in different coffees and caffeine-containing drinks as well as that of theobromine intake. No increased risk was found in post-menopausal women in association with total caffeine and total methylxanthine intake. In pre-menopausal women the increased risk at higher levels of intake was not statistically significant and not dose-dependent. 164 ; Data collected in the Collaborative Perinatal Project were assessed for association of theophylline intake and risk of stillbirth in a total sample of 51, 830 singleton pregnancies. Theophylilne ingested by pregnant women does not appear to increase their risk of delivering a stillbirth. reproductive developmental toxicity. Electrophysiologic analysis of both primary -cells and INS-1 cells also revealed that Ca2 + current amplitude is reduced by long-term treatment with genistein. This was confirmed by our expression analysis showing a significant decrease in the mRNA level of the L-type Ca2 + channel subunit, 1C. L-type Ca2 + channels are reported to be responsible for 5090% of total Ca2 + current in mouse -cells Plant 1988, Gilon et al. 1997, Schulla et al. 2003 ; . Analysis of -cell Ca2 + currents from mice with a specific ablation of the 1C subunit in these cells reveals that 1C is responsible for all L-type Ca2 + current in mouse -cells Schulla et al. 2003 ; . The genistein-induced Ca2 + channel downregulation underlies the diminished Ca2 + influx upon high glucose stimulation and at least partially explains the reduced depolarization-induced insulin vesicle exocytosis in genistein-treated cells. The loss of Ca2 + oscillations in these cells is more likely to be due to the reduction in KATP rather than Ca2 + channel expression, as Ca2 + oscillations in -cells result from the reopening of KATP channels after depolarization Larsson et al. 1996, Rolland et al. 2002 ; . The decreased Ca2 + currents may also underlie the lack of action potential firing in response to glucose stimulation in genistein-treated cells. Action potentials in primary mouse -cells are generated by the opening of Ca2 + channels Mears 2004 ; , as voltage-dependent Na + channels, which typically initiate action potentials in many electrically excitable cells, are inactivated at physiologic membrane potentials in -cells of this species Gopel et al. 1999 ; . Blockade of L-type Ca2 + channels in -cells suppresses glucose-induced bursting activity, [Ca2 + ]i oscillations and insulin secretion Ashcroft & Rorsman 1989 hence, the decrease in 1C expression and Ca2 + current size in genistein-treated cells appears to explain at least partially the loss of these functions in our experiments. Exocytosis of insulin, as measured by membrane capacitance changes, was significantly reduced in genistein-treated cells. This contrasts with the acute application of genistein, which causes an increase in glucose-stimulated insulin secretion in mouse -cells Jonas et al. 1995 ; . However, the authors of this work concluded that this effect of genistein was not due to any direct effect on PTK. The similarity in whole-cell capacitance in both our treatment groups indicates that the reduction in exocytosis we observed is not due to any experimental bias caused by recording from smaller cells. The decrease in secretion appeared to occur most significantly in a subset of early release granules. This granule pool is characterized as a subset of docked secretory vesicles which are immediately ready for release into the extracellular space upon cell excitation Kanno et al. 2004 ; . L-type Ca2 + channel activity has been shown to be highest in -cells in areas where clusters of vesicles are docked at the cell membrane. Schools were human corona services frequently theophylline separated and albenza. Table 1. Evidence-based Rating Criteria for Safety. Temperature; stable for 12 hours in NS if refrigerated. Final concentration of busulfan should be approximately 0.5 mg mL and albendazole, because salbutamol theophylline. The occurrence of adverse effects with theophylline, even at levels in the therapeutic range, and the severity of its effects in acute and chronic overdose are notable; however, theophylline continues to be prescribed for some patients. Sient and reversible, and two studies24, 27 reported only minimal side effects from the administration of low-dose methotrexate. No bone marrow toxicity was observed at the dosages used, and follow-up was too short to address issues of potential hepatic fibrosis. Methotrexate competes with the hepatic metabolism of theophylline, with an average decrease in theophylline clearance of 19% in one case series.18 Methotrexate is well-known to cause a variety of pulmonary manifestations, including drug-induced hypersensitivity reaction, chronic pneumonitis and fibrosis, bronchiolitis obliterans with organizing pneumonia, noncardiogenic pulmonary edema, and bronchospasm.40 The significance of these side effects in asthma patients has not been investigated, although it has raised significant editorial debate.41 Troleandomycin Mechanism of Action: Troleandomycin TAO ; is a macrolide antibiotic that was introduced in 1957 and was first described as a treatment for steroiddependent asthma in 1974.42 The results of studies examining its mechanism of action have been conflicting, but the drug is believed to have a synergistic effect when administered with oral corticosteroids. In vitro data using its parent compound, oleandomycin, at a concentration of 5 g demonstrated a 44% reduction in the concentration of methylprednisolone that was required to inhibit human lymphocyte blast transformation by 50% p 0.005 ; .43 It is believed that TAO alters corticosteroid bioavailability by decreasing hepatic metabolism and excretion. The addition of 14 mg kg d TAO to the regimen of 10 severe steroid-dependent asthma patients resulted in a reduction in clearance of IV methylprednisolone by a mean of 60 18.7 and spironolactone. Theophylline sr inwood labsResults from Figure 2b confirm the importance of the apoptotic pathway in the SSRIinduced cell death as over-expression of anti-apoptotic Bcl-2 protected the BL cells from all 3 drugs tested. Thus while cells carrying empty control ; vector lost the light scatter characteristics of the viable subpopulation indicated in black ; and moved to the dead gate indicated in red ; in response to SSRI those expressing the vector containing bcl-2 remained in the viable sector and anacin. Theophylline er, 22 theophylline td, 22 THERACYS, 40 THERA-FLUR-N, 92 thermazene, 73 THIOGUANINE, 40 THIOLA, 82 thioridazine hcl, 43 thioridazine hcl intensol, 43 thiothixene, 43 THORAZINE, 43 THYMOGLOBULIN, 46 thyroid, 109 THYROID AGENTS, 109 THYROLAR-1, 109 THYROLAR-1 2, 109 THYROLAR-1 4, 109 THYROLAR-2, 109 THYROLAR-3, 109 TIAZAC 120 MG CAPSULE SA, 48 TIAZAC 180 MG CAPSULE SA, 48 TIAZAC 240 MG CAPSULE SA, 48 TIAZAC 300 MG CAPSULE SA, 48 TIAZAC 360 MG CAPSULE SA, 48 TIAZAC 420 MG CAPSULE SA, 48 TICE BCG, 40 TICLID, 83 ticlopidine hcl, 83 TIGAN, 29 TIKOSYN, 20 TILADE, 22 time-hist, 63 TIMENTIN, 106 TIMOLIDE 10 25, 35 timolol 0.25% eye drops, 101 timolol 0.5% eye drops, 101 timolol maleate 10 mg tablet, 47 timolol maleate 20 mg tablet, 47 timolol maleate 5 mg tablet, 47 timolol maleate ophthalmi, 101 TIMOPTIC, 102 TIMOPTIC OCUDOSE, 102 TIMOPTIC-XE, 102 TINDAMAX, 36 tizanidine hcl, 96 t-naf, 92 TOBRADEX, 102 tobramycin 0.3% eye drops, 102 tobramycin 1.2 gm vial, 7 tobramycin 10 mg ml vial, 7! 1. African pharmacopoeia. Vol. 1, 1st ed. Lagos, Organization of African Unity, Scientific Technical & Research Commission, 1985. 2. The Japanese pharmacopoeia, 13th ed. English version ; . Tokyo, Ministry of Health and Welfare, 1996. 3. European pharmacopoeia, 3rd ed. Strasbourg, Council of Europe, 1996. 4. Hooker JD, Jackson BD. Index Kewensis. Vol. 1. Oxford, Clarendon Press, 1895. 5. Farnsworth NR, ed. NAPRALERT database. Chicago, University of Illinois at Chicago, IL, February 9, 1998 production an online database available directly through the University of Illinois at Chicago or through the Scientific and Technical Network [STN] of Chemical Abstracts Services ; . 6. Bisset NG. Herbal drugs and phytopharmaceuticals. Boca Raton, FL, CRC Press, 1994. 7. Youngken HW. Textbook of pharmacognosy, 6th ed. Philadelphia, PA, Blakiston, 1950. 8. Bruneton J. Pharmacognosy, phytochemistry, medicinal plants. Paris, Lavoisier, 1995. 9. Quality control methods for medicinal plant materials. Geneva, World Health Organization, 1998. 10. Guidelines for predicting dietary intake of pesticide residues, 2nd rev. ed. Geneva, World Health Organization, 1997 document WHO FSF FOS 97.7 ; . 11. Kanazawa H et al. Determination of acidic saponins in crude drugs by highperformance liquid chromatography on octadecylsilyl porous glass. Journal of Chromatography, 1993, 630: 408414. Hayashi S, Kameoka H. Volatile compounds of Polygala senega L. var. latifolia Torrey et Gray roots. Flavour and Fragrance Journal, 1995, 10: 273280 and panadol. A total of 5, 672 patients with a diagnosis of COPD met the cohort selection criteria. Tables 1 and 2 present a summary of the baseline characteristics of the cohort. Medicaid patients with COPD were primarily women 61.02% ; between 55 and 64 years of age 47.46% ; . Most of these patients were white 54.21% ; . We extracted a total of 1, 067, 756 medical claims and 720, 127 pharmacy claims. Among the 1, 067, 756 medical claims 78.59% office and outpatient visits, 21.20% inpatient care, and 0.21% emergency visits ; , a total of 84, 451 7.91% ; claims were directly related to COPD as a primary diagnosis. Those claims were disaggregated as follows: 35.39% of claims were related to chronic bronchitis ICD-9 491 ; . 5.77% of claims were related to emphysema ICD-9 492 ; . 58.84% of claims were related to chronic airway obstructive diseases ICD-9 496 ; . Of the 720, 127 pharmacy claims, 148, 341 20.60% ; were directly associated with drug prescriptions that could be related to COPD, such as ipratropium bromide e.g., Atrovent, Boehringer Ingelheim ; , salmeterol xinafoate e.g., Serevent Diskus, GlaxoSmithKline ; , albuterol e.g., Proventil, Schering; Ventolin, GlaxoSmithKline ; , and the0phylline e.g., Theo-Dur, Key; Theolair, 3M. Index sulfathiazole 15 f. sulfenamide 94 f., 97, 103, 126 ff., 133 sulfisoxalole 15 f. sulfonamides 54, 316 sulindac 517 sulpiride 18 sultamicillin 494 sumatriptan 26, 43 ff., 531 surmountable antagonist 164 sustained duration of action 191 sweating 279 sydnonimines 256 sympathomimetic, indirect 60 syncope 247 synergistic effect 436 systemic corticosteroid therapy 424 synthetic glucocorticoids 422 syphilis 315 systemic infections 319 systemic safety profile 436 systolic blood pressure SBP ; 165 systolic diastolic blood pressures 165, 183 S-8307 40, 157 f. S-8308 40, 158 f. tenoxicam 519 teprotide 157, 169 f. teratogenicity 13, 175 terazosin 455 terbutaline 542 terfenadine 411 f., 414 testicular cancer 387, 389 testosterone 62, 397, 481 tetracaine 475 tetracyclines 316, 346, 350, tetryzoline 552 thalidomide 13 thebaine 261 f., 267 thebaine analogues 266 theopphylline 76, 352 therapeutic space 66 therapeutic window 153, 289 thermal stability 343 thiamphenicol 6, 7 thioridazine 298, 307 thrombin inhibitors 59 thromboxan-A2 TXA-2 ; 161 thymus gland 86 thymus involution 425 thyroid gland 86 f. thyroid tumor 373 thyrotoxicosis 200 thyrotropin-releasing hormone 26 tiagabine 7 tiaprofenic acid 520 TIBET study 205 ticarcillin 491 ticlopidine 453 tifluadom 57 f. tiludronic acid tiludronate ; 374, 377, 380 timolol 197, 460 timoprazole 84, 86 ff., 98, 103, 111, ff., 122, 125, 127 f. tioconazole 503 tiprenolol 197 tiquinamide 119 f. tiospirone 26 f., 43, 46 f. tiotidine 76 f. tiotropium bromide 28, 447 tirilazad 62 tissue regeneration 160 tobramycin 507 tolamolol 197, 225 tolcapone 4 f. tolerance 261, 267, 274 toliprolol 197 tolnaftate 26 tomoxetine 33 and acetaminophen. Mechanism of action : theophylllne relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Acquired inhibitors f8 more common than f9 ; may be associated with underlying medical problems such as malignancy or vasculitis and there is no association with congenital haemophilia and anafranil. It is especially important to check with your doctor before combining zantac with the following: alcohol blood-thinning drugs such as coumadin diazepam valium ; diltiazem cardizem ; enoxacin penetrex ; glipizide glucotrol ; glyburide diabeta, micronase ; itraconazole sporanox ; ketoconazole nizoral ; metformin glucophage ; nifedipine procardia ; phenytoin dilantin ; procainamide procan sr ; sucralfate carafate ; theophylline theo-dur ; triazolam halcion ; special information if you are pregnant or breastfeeding the effects of zantac in pregnancy have not been adequately studied. North Brunswick, NJ 08902, USA P: 732 ; 214-1550 F: 732 ; 745-7270 W: njtechcentre The Technology Centre of New Jersey offers growing firms and large established companies, a way to afford modern laboratory and production facilities that are customized to specific research and development needs. Large or small, the NJ Economic Development Authority will work to help program specific fit-out, while controlling costs and providing management services, leaving you time for research and development. New York Biotechnology Association Exhibit Space: 720 New York Pavilion Karin Duncker 666 Third Avenue, 24th Floor New York, NY 10017, USA P: 212 ; 661-1780 F: 212 ; 661-1779 W: nyba The New York Biotechnology Association is a not-for-profit trade association with over 260 members, dedicated to the development and growth of New York State based biotechnology related industries and institutions. In 2003 NYBA launched a new campaign, The Cures Start Here, to boost awareness of New York State's biotechnology cluster, and amplify all of the good news coming out of our industry, strengthening the State's position as a global location for biotechnology. New York City Economic Development Corporation Exhibit Space: 716 New York State Pavilion William Fair 110 William Street, New York, NY 10038, US P: 212 ; 312-3836 F: 212 ; 312-3917 W: nycedc The Bioscience Industry Desk at New York City's Economic Development Corporation offers you NYC's world-class research institutions, outstanding scientific workforce, and internationally renowned financial markets. NYC's diverse populatin and prestigous teaching hospitals provide the ideal environment for clinical trials. Our incentive programs and NYC's assets will ensure your success. New York State Exhibit Booth: 722 New York Pavilion Louis Garguilo 30 South Pearl Street, Albany, NY 12245 P: 518-292-5200 F: 518-292-5810 W: empire ate.ny New York State Loves Biotech. The Empire State is proud to be a sponsor of BIO 2004, and we look forward to meeting interested companies and individuals at the show. New York has long been at the forefront of the country's biomedical industry. Its reputation in medical research was built on worldrenown hospitals and research centers, and now the State is leading the way in biotechnology. New York and clomipramine and theophylline, for instance, dose of theophylline. Synopsis Additional topics have been referred to NICE for inclusion in its forward work programme. These include the management and care of drug misuse, drugs for prostate cancer, and management of ADHD. Asthma and COPD Guidelines Both the Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma EPR-2 ; 1 and the Global Initiative for Chronic Obstructive Lung Disease GOLD ; guidelines recommend smooth muscle relaxants as possible alternative treatment to first-line therapies.5 Clinical Trials Several well-controlled studies have demonstrated the efficacy of theophylline in suppressing the symptoms of chronic asthma38-41 and exercise-induced bronchospasm 42, 43 . In one study theophylline in individualized doses resulting in an average serum concentration of 13 mcg mL was significantly more effective in suppressing symptoms and reducing the need for emergency medication than conventional doses combined with ephedrine at an average serum concentration of 6.5 mcg mL or placebo38. Furthermore, even in patients with steroid-dependent asthma, the addition of therapeutic doses of theophylline decreased symptoms, improved exercise tolerance, and decreased the need for inhaled sympathomimetics and short courses of daily corticosteroids during exacerbations as compared to placebo when both were added to the chronic steroid regimen40. VII. Conclusions and aralen. Digoxin tablet and theophylline capsuleLow theophylline levelTheophylline warfarin interactionDistributed by Oxford University Press since 1993 to non-members of the European Association of Public Health. Volume 4, 1994, 4 issues. Alternative alone is also acceptable. Only if monotherapy with two or three different substances proves inadequate a dual combination is prescribed. BROMOTRYPTAMINE BROMOURACIL-5 bromouridine bromovincamine-11 bromovinylarauridine-5 BROMOVINYLARAURIDINE- TRIPHOSPHATE BROMOVINYLDEOXYCYTIDINE bromovinyldeoxyuridine BROMOVINYLDEOXYURIDINE- DIPHOSPHATE BROMOVINYLDEOXYURIDINE- MONOPHOSPHATE BROMOVINYLDEOXYURIDINE- TRIPHOSPHATE BROMOVINYLESTRADIOL-17-ALPHA BROMOVINYLURACIL-5 BROMOVINYLURIDINE-5 BROMOVULONE-I BROMOXANIDE BROMPERIDOL h.t. h.t. h.t. h.t. VIRUCIDES CYTOSTATICS ANTHELMINTICS DOPAMINE-ANTAGONISTS NEUROLEPTICS PSYCHOSEDATIVES PSYCHOSEDATIVES NEUROLEPTICS DOPAMINE-ANTAGONISTS ANTIHISTAMINES-H1 use use use was h.t. h.t. use was h.t. h.t. h.t. h.t. BROXURIDINE BROVINCAMINE SORIVUDINE BROMOVINYLARAURIDINE-5 VIRUCIDES VIRUCIDES CYTOSTATICS brivudine BROMOVINYLDEOXYURIDINE VIRUCIDES VIRUCIDES VIRUCIDES ESTROGENS BRONCHOCONSTRICTOR BRONCHODILATOR BRONCHODILATORS BRONCHOMALACIA * BRONCHOPARAT bronchopneumonia BRONCHOPULMONARY * BRONCHORETARD BRONCHORREA BRONCHOSCOPY BRONCHOSPASM * BRONCHOSPASMIN BRONCHUS BRONCOPLUS * BRONDAXIN BRONIDIOL BRONIDOX * BRONKODYL-SR * BRONKOSOL BRONOPOL * BRONOX BRONSON BRONZE bronze-diabetes use h.t. BRONZE LINK DIABETES PANCREOPATHY HEPATOPATHY CARBOHYDRATE-METAB. DISORDER ESTROGENS ANALGESICS ANTIPYRETICS ANTIINFLAMMATORIES IMMUNOSTIMULANTS CYTOSTATICS VIRUCIDES INTERFERON-INDUCERS ANTISEPTICS h.t. THEOPHYLLINE ISOETARINE ANTISEPTICS OXOLAMINE h.t. h.t. h.t. h.t. h.t. h.t. THEOPHYLLINE PNEUMOPATHY DIAGNOSIS PNEUMOPATHY REPROTEROL LUNG MUCOLYTICS CHOLINE-THEOPHYLLINATE ANTISEPTICS use h.t. PNEUMOPATHY THEOPHYLLINE-SODIUM- GLYCINATE BRONCHIAL LINK PNEUMONIA.
|
